Istaroxime

Windtree Therapeutics, Inc. announced a new strategy to become revenue-generating by acquiring small biotech companies with FDA-approved products, while continuing its cardiovascular and oncology pipeline development. The company aims to leverage its commercialization expertise to optimize performance across future subsidiaries, using equity for acquisitions.

Windtree Therapeutics announces a strategy to acquire small companies with FDA-approved products to generate revenue, while advancing its cardiovascular and oncology pipeline. The company aims to leverage its commercialization expertise to optimize performance across future subsidiaries, using equity for acquisitions.

Windtree Therapeutics, Inc. announced a new strategy to become revenue-generating by acquiring small biotech companies with FDA-approved products, while continuing its cardiovascular and oncology pipeline development. The company aims to leverage its commercialization expertise to optimize performance across future subsidiaries, using equity for acquisitions.

Windtree Therapeutics announced Dr. Alexandre Mebazaa presented positive istaroxime data from the Phase 2b SEISMiC B study in early cardiogenic shock at the Cardiovascular Clinical Trials Conference. Istaroxime aims to improve cardiac function and blood pressure without increasing heart rate or causing arrhythmias, maintaining renal function.

Windtree Therapeutics announced Dr. Alexandre Mebazaa's presentation on istaroxime's Phase 2b SEISMiC B study data at the Cardiovascular Clinical Trials Conference. Istaroxime, a novel therapy for early cardiogenic shock, aims to improve cardiac function and blood pressure with a favorable safety profile. The company believes pharmacologic innovation is crucial for cardiogenic shock treatment.

Windtree Therapeutics engages New Growth Advisors to explore out-licensing or asset sale of its cardiovascular portfolio, leveraging positive Phase 2b results in cardiogenic shock. The company aims to secure non-dilutive funding and expand its out-licensing process.

Windtree Therapeutics reports Q3 2024 financial results and significant progress in istaroxime studies for cardiogenic shock, securing $13.9 million in private placements and a $35 million equity line. The company plans to accelerate istaroxime SCAI Stage C cardiogenic shock study enrollment with interim data expected in Q2 2025.

Windtree Therapeutics advances istaroxime for cardiogenic shock, initiating SEISMiC C trial in SCAI Stage C patients. Positive Phase 2 data supports Phase 3 readiness, with plans for regulatory discussions in 2025. The company expands its patent portfolio and explores licensing opportunities, aiming to position istaroxime as a superior therapy for heart failure with a favorable safety profile.

Windtree Therapeutics announces CEO Craig Fraser will present at the ThinkEquity Conference on Oct 30th, discussing positive Phase 2b SEISMiC Extension Study results for istaroxime in heart failure and company strategy.